IBI-3005
- Generic Name
- IBI-3005
Study of IBI3005 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- UnresectableLocally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT06418061
- Locations
- 🇨🇳
Shandong Cancer Hospital & Institute, JiNan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath